Q-omics provides the consensus-scored IGHV3OR16-12 profile across patient tissues and cancer cell-line models. IGHV3OR16-12 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, IGHV3OR16-12 is differentially expressed in 7, with the highest sampling consensus in COAD. Additionally, IGHV3OR16-12 protein abundance shows 22,865 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight HNSC, COAD, and PDAC as cancer lineages where IGHV3OR16-12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IGHV3OR16-12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IGHV3OR16-12 survival associations across molecular data types. IGHV3OR16-12 RNA expression shows survival associations in the most cancer types (21), followed by mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IGHV3OR16-12 RNA expression–survival associations across cancer types. High IGHV3OR16-12 expression shows favorable associations in HNSC, SKCM, UCEC, LUAD, BRCA and UCS. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for IGHV3OR16-12 RNA expression.
This table summarizes IGHV3OR16-12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for IGHV3OR16-12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IGHV3OR16-12 shows lower tumor expression in COAD, BRCA, READ and STAD and higher tumor expression in LUAD and KIRC. The COAD box plot shows higher IGHV3OR16-12 RNA expression in normal versus tumor tissue (log2 FC = −1.191, t-test p < 0.001).
This table shows molecular features associated with IGHV3OR16-12 in patient tissues and cancer cell lines. In patient samples, IGHV3OR16-12 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set.
